ABSTRACT
We aimed to identify circRNAs associated with Parkinson’s disease (PD) by leveraging 1,848 participants and 1,789 circRNA from two of the largest publicly available studies with longitudinal clinical and blood transcriptomic data. To comprehensively understand changes in circRNAs we performed a cross-sectional study utilizing the last visit of each participant, and a longitudinal (mix model) analysis that included 1,166 participants with at least two time points. We identified 192 circRNAs differentially expressed in PD participants compared to healthy controls, with effects that were consistent in the mixed models, mutation carriers, and diverse ancestry. Finally, we included the 149 circRNA in a model with a ROC AUC of 0.825, showing that have the potential to aid the diagnosis of PD. Overall, we demonstrated that circRNAs play an important role in PD and can be leveraged as biomarkers.
Competing Interest Statement
The funders of the study had no role in the collection, analysis, or interpretation of data; in the writing of the report; or in the decision to submit the paper for publication. CC is a member of the advisory board of Vivid genetics, Halia Therapeutics and ADx Healthcare and has received research support from Biogen, EISAI, Alector and Parabon. The rest of the authors report no conflict of interest.
Funding Statement
This work was supported by grants from the Department of Defense (W81XWH2010849), Bright Focus Foundation (A2021033S), Michael J. Fox Foundation (MJFF-021599), National Institute of Health (P30AG066444, R00AG062723, U19AG03243812, R01AG053267), Alzheimers Association (DIAN-TU-PP-22-872356 and DIANTUOLE21725093) and an NGI Pilot Grant.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
We accessed the largest PD blood RNAseq datasets publicly available to date from the PDBP and PPMI studies. PPMI: https://www.ppmi-info.org/access-data-specimens/download-data PDBP: https://www.amp-pd.org/register-for-amp-pd
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data are openly available from the PDBP and PPMI studies
https://www.ppmi-info.org/access-data-specimens/download-data
